• 15/07/2022-29/04/2024

Biogena (A.P.I) LTD has earned within the contexts of the operational program «Θ.Αλ.Ε.Ι.Α» 2021-2027 a public funding for the implementation of it. Through this program, the company will invest in the purchase of new LC-MS/MS.

‘The Project is funded by the European Union through the Ministry of Energy, Commerce and Industry’

• Development and Scale-Up Manufacturing of Therapeutic Peptides (CYTIDES), CODEVELOP-ICT-HEALTH/0322/0038

First time in Cyprus that Academia and an API (Active Pharmaceutical Ingredient) manufacturer collaborate towards the co-development of generic therapeutic peptides.

CYTIDES enhances the effective collaboration between the pharma industry (BIOGENA API) and the research community (Laboratory of Peptide Chemistry – University of Nicosia Research Foundation – UNRF) in innovative technologies sharing knowledge, resources, and infrastructures.

‘The Project is funded by the European Union – NextGenerationEU, through the Research and Innovation Foundation’

• 14/12/2022-13/06/2023

Green techniques in peptide synthesis, INNOVOUCHER/0722/0009

Biogena A.P.I Ltd in collaboration with the Laboratory of Peptide Chemistry – University of Nicosia Research Foundation – UNRF have been funded for a project under the Technological Development and Innovation “RESTART 2016 – 2020”.

‘The Project is funded by the European Union – NextGenerationEU, through the Research and Innovation Foundation’

• Innovative drug formulation for targeted release of Rifaximin based on polymer nanotechnology (INNOVATE/0719/0083)

Biogena A.P.I Ltd in collaboration with Medochemie Ltd (a generic pharmaceutical company) have been funded for a project under the Technological Development and Innovation “RESTART 2016 – 2020”.

‘The Project is funded by the European Union – NextGenerationEU, through the Research and Innovation Foundation’